Bartelds et al. [9] demonstrated that two-thirds of ADAs-positive RA patients developed antibodies within the first 28 weeks, which correlated with lower serum adalimumab levels and an increased rate of treatment discontinuation. This evidence concerns the gene AGPS and rheumatoid arthritis.